JP2004536045A - 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法 - Google Patents

基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法 Download PDF

Info

Publication number
JP2004536045A
JP2004536045A JP2002576969A JP2002576969A JP2004536045A JP 2004536045 A JP2004536045 A JP 2004536045A JP 2002576969 A JP2002576969 A JP 2002576969A JP 2002576969 A JP2002576969 A JP 2002576969A JP 2004536045 A JP2004536045 A JP 2004536045A
Authority
JP
Japan
Prior art keywords
cyclopamine
treatment
cells
bcc
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002576969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536045A5 (enExample
Inventor
タシ、シナン
アヴチ、オクタイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2004536045(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2004536045A publication Critical patent/JP2004536045A/ja
Publication of JP2004536045A5 publication Critical patent/JP2004536045A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2002576969A 2001-07-02 2001-07-02 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法 Pending JP2004536045A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009074496A Division JP2009143963A (ja) 2009-03-25 2009-03-25 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物

Publications (2)

Publication Number Publication Date
JP2004536045A true JP2004536045A (ja) 2004-12-02
JP2004536045A5 JP2004536045A5 (enExample) 2005-10-06

Family

ID=21619326

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002576969A Pending JP2004536045A (ja) 2001-07-02 2001-07-02 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法
JP2010028010A Expired - Fee Related JP5424923B2 (ja) 2001-07-02 2010-02-10 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
JP2013193304A Ceased JP2014028834A (ja) 2001-07-02 2013-09-18 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010028010A Expired - Fee Related JP5424923B2 (ja) 2001-07-02 2010-02-10 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
JP2013193304A Ceased JP2014028834A (ja) 2001-07-02 2013-09-18 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用

Country Status (14)

Country Link
EP (4) EP2862570A1 (enExample)
JP (3) JP2004536045A (enExample)
KR (1) KR20090125833A (enExample)
CN (2) CN1525859B (enExample)
AT (2) ATE305300T1 (enExample)
AU (1) AU2001272892B8 (enExample)
BR (1) BR0117063A (enExample)
CA (1) CA2452151C (enExample)
DE (2) DE60113733T2 (enExample)
DK (2) DK1401438T3 (enExample)
ES (3) ES2534400T3 (enExample)
PT (1) PT1411938E (enExample)
RU (1) RU2312661C2 (enExample)
WO (2) WO2002078703A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
AU2006283040B2 (en) 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
MY181496A (en) * 2006-10-31 2020-12-23 Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
NZ579361A (en) * 2007-03-07 2012-04-27 Infinity Discovery Inc Heterocyclic cyclopamine analogs and methods of use thereof
US7964590B2 (en) 2007-03-07 2011-06-21 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
HK1211887A1 (en) 2013-02-04 2016-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN104740633A (zh) * 2013-12-26 2015-07-01 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2017139497A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
CA3227688A1 (en) 2021-09-13 2023-03-02 Sinan Tas Effective interventions with aging and diseases of aging of human and their consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
ATE466850T1 (de) * 1998-09-23 2010-05-15 Res Dev Foundation Tocopherole, tocotrienole, sonstige chroman- und seitenkettenderivate, sowie deren verwendungen
AU780358B2 (en) * 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
EP1646395B8 (en) * 1999-11-30 2014-12-17 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物

Also Published As

Publication number Publication date
DE60204966T2 (de) 2006-05-18
CA2452151C (en) 2012-01-03
ATE305300T1 (de) 2005-10-15
DK1401438T3 (da) 2006-02-13
BR0117063A (pt) 2004-07-27
WO2002078704A1 (en) 2002-10-10
EP1561464A3 (en) 2007-04-25
RU2004103074A (ru) 2005-05-10
DE60113733T2 (de) 2006-06-29
AU2001272892B2 (en) 2006-03-16
ES2534400T3 (es) 2015-04-22
DE60204966D1 (de) 2005-08-11
CN1525859B (zh) 2010-05-05
KR20090125833A (ko) 2009-12-07
WO2002078703A1 (en) 2002-10-10
ES2250434T3 (es) 2006-04-16
EP1561464A2 (en) 2005-08-10
PT1411938E (pt) 2005-11-30
AU2001272892B8 (en) 2006-05-04
DK1411938T3 (da) 2005-11-07
EP1401438B1 (en) 2005-09-28
JP2010132691A (ja) 2010-06-17
JP2014028834A (ja) 2014-02-13
EP2216022B1 (en) 2015-01-07
EP2862570A1 (en) 2015-04-22
EP2216022A1 (en) 2010-08-11
CN1525859A (zh) 2004-09-01
RU2312661C2 (ru) 2007-12-20
DE60113733D1 (de) 2006-02-09
CA2452151A1 (en) 2002-10-10
ES2246011T3 (es) 2006-02-01
WO2002078703A8 (en) 2003-06-12
JP5424923B2 (ja) 2014-02-26
CN1522146A (zh) 2004-08-18
ATE299022T1 (de) 2005-07-15
EP1401438A1 (en) 2004-03-31
CN1230169C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
JP2004536045A (ja) 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法
US7893078B2 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
AU2001272892A1 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
US20140242012A1 (en) Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
Gorai et al. Update of pathophysiology and treatment options of seborrheic keratosis
JP2012236815A (ja) ナス属（ｓｏｌａｎｕｍｇｅｎｕｓ）植物からの水溶性抽出物での炎症及び皮膚の光損傷の治療及び／又は予防、並びに皮膚の光防護
JP2009143963A (ja) 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
US20170326118A1 (en) Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CN114432295A (zh) 野黄芩素在制备预防或治疗瘢痕的药物中的用途
RU2308948C2 (ru) Применение циклопамина для лечения базально-клеточной эпителиомы (карциномы) и других опухолей
JP2014028835A (ja) 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法
TW201632182A (zh) 治療皮膚之腫瘤及癌前病理的雷公藤內酯及其衍生物
US20120258937A1 (en) Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis
Das et al. Malignant diseases of the skin
CN121015680A (zh) 野黄芩苷与红景天苷联合在治疗日光性皮炎中的应用
CN120227375A (zh) 一种RNA m6A调控剂组合物及其制备方法与应用
HK1096597A (en) Use of cyclopamine in the treatment of psoriasis and other skin disorders
CN101904852A (zh) 环杷明在治疗基底细胞癌及其它肿瘤中的应用
CZ293895B6 (cs) Farmaceutický přípravek pro topickou aplikaci

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20071019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090325

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090610

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20091120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110609

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120120